Inflammation as Prognostic Hallmark of Clinical Outcome in Patients with SARS-CoV-2 Infection
2023
Diana Fuzio | Angelo Michele Inchingolo | Vitalba Ruggieri | Massimo Fasano | Maria Federico | Manuela Mandorino | Lavinia Dirienzo | Salvatore Scacco | Alessandro Rizzello | Maurizio Delvecchio | Massimiliano Parise | Roberto Rana | Nicola Faccilongo | Biagio Rapone | Francesco Inchingolo | Antonio Mancini | Maria Celeste Fatone | Antonio Gnoni | Gianna Dipalma | Giovanni Dirienzo
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is often characterized by a life-threatening interstitial pneumonia requiring hospitalization. The aim of this retrospective cohort study is to identify hallmarks of in-hospital mortality in patients affected by Coronavirus Disease 19 (COVID-19). A total of 150 patients admitted for COVID-19 from March to June 2021 to &ldquo:F. Perinei&rdquo: Murgia Hospital in Altamura, Italy, were divided into survivors (n = 100) and non-survivors groups (n = 50). Blood counts, inflammation-related biomarkers and lymphocyte subsets were analyzed into two groups in the first 24 h after admission and compared by Student&rsquo:s t-test. A multivariable logistic analysis was performed to identify independent risk factors associated with in-hospital mortality. Total lymphocyte count and CD3+ and CD4+ CD8+ T lymphocyte subsets were significantly lower in non-survivors. Serum levels of interleukin-6 (IL-6), lactate dehydrogenase (LDH), C-reactive protein (CRP) and procalcitonin (PCT) were significantly higher in non-survivors. Age >: 65 years and presence of comorbidities were identified as independent risk factors associated with in-hospital mortality, while IL-6 and LDH showed a borderline significance. According to our results, markers of inflammation and lymphocytopenia predict in-hospital mortality in COVID-19.
显示更多 [+] 显示较少 [-]